Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 6 | 2025 | 241 | 0.830 |
Why?
|
| Protoporphyria, Erythropoietic | 1 | 2018 | 2 | 0.570 |
Why?
|
| Cholestasis | 1 | 2018 | 166 | 0.480 |
Why?
|
| Hypertension, Portal | 2 | 2020 | 76 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2025 | 38 | 0.270 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2007 | 5 | 0.260 |
Why?
|
| Histiocytoma, Benign Fibrous | 1 | 2007 | 10 | 0.260 |
Why?
|
| Carcinoma | 2 | 2021 | 279 | 0.250 |
Why?
|
| Iodine Radioisotopes | 1 | 2025 | 65 | 0.240 |
Why?
|
| Conjunctiva | 1 | 2007 | 189 | 0.230 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 393 | 0.220 |
Why?
|
| Eosinophilic Esophagitis | 2 | 2016 | 76 | 0.210 |
Why?
|
| Pyridines | 1 | 2025 | 251 | 0.210 |
Why?
|
| Nocardia Infections | 1 | 2024 | 13 | 0.210 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2024 | 52 | 0.200 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 59 | 0.200 |
Why?
|
| Loss of Function Mutation | 1 | 2024 | 151 | 0.200 |
Why?
|
| Pyrazoles | 1 | 2025 | 330 | 0.200 |
Why?
|
| Insulins | 1 | 2022 | 18 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1562 | 0.190 |
Why?
|
| Homozygote | 1 | 2024 | 540 | 0.180 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2021 | 8 | 0.180 |
Why?
|
| Child | 17 | 2024 | 25352 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 743 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2024 | 210 | 0.170 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1238 | 0.170 |
Why?
|
| Granuloma, Pyogenic | 1 | 2020 | 6 | 0.170 |
Why?
|
| Thyroid Gland | 1 | 2021 | 99 | 0.170 |
Why?
|
| Cough | 2 | 2020 | 97 | 0.160 |
Why?
|
| Adolescent | 16 | 2025 | 20176 | 0.160 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 90 | 0.160 |
Why?
|
| Lung Neoplasms | 2 | 2020 | 1494 | 0.160 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 284 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2007 | 880 | 0.150 |
Why?
|
| Mutation, Missense | 1 | 2024 | 889 | 0.150 |
Why?
|
| Orchiectomy | 1 | 2019 | 53 | 0.150 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 717 | 0.150 |
Why?
|
| Trachea | 1 | 2020 | 204 | 0.150 |
Why?
|
| Liver Diseases | 2 | 2024 | 381 | 0.150 |
Why?
|
| Osteosarcoma | 2 | 2018 | 261 | 0.150 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 85 | 0.140 |
Why?
|
| Radiotherapy | 1 | 2019 | 120 | 0.140 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2018 | 4 | 0.140 |
Why?
|
| Provitamins | 1 | 2018 | 3 | 0.140 |
Why?
|
| Cholestyramine Resin | 1 | 2018 | 13 | 0.140 |
Why?
|
| Photosensitivity Disorders | 1 | 2018 | 10 | 0.140 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 54 | 0.140 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 120 | 0.140 |
Why?
|
| Cholagogues and Choleretics | 1 | 2018 | 24 | 0.140 |
Why?
|
| Portal Vein | 1 | 2018 | 88 | 0.140 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2018 | 39 | 0.140 |
Why?
|
| Laser Therapy | 1 | 2020 | 230 | 0.140 |
Why?
|
| Pruritus | 1 | 2018 | 48 | 0.140 |
Why?
|
| beta Carotene | 1 | 2018 | 36 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 112 | 0.140 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 139 | 0.140 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 417 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2022 | 665 | 0.130 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 226 | 0.130 |
Why?
|
| Biliary Atresia | 1 | 2020 | 217 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 34 | 0.130 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 41 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 124 | 0.130 |
Why?
|
| Wolman Disease | 1 | 2016 | 7 | 0.130 |
Why?
|
| Polyps | 1 | 2017 | 40 | 0.130 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2017 | 106 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2018 | 128 | 0.130 |
Why?
|
| Male | 18 | 2024 | 62943 | 0.120 |
Why?
|
| Esophageal Mucosa | 1 | 2016 | 12 | 0.120 |
Why?
|
| Galectin 3 | 1 | 2016 | 31 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 262 | 0.120 |
Why?
|
| Humans | 26 | 2025 | 127593 | 0.120 |
Why?
|
| Fluticasone-Salmeterol Drug Combination | 1 | 2015 | 9 | 0.120 |
Why?
|
| Itraconazole | 1 | 2015 | 23 | 0.120 |
Why?
|
| Budesonide | 1 | 2015 | 19 | 0.120 |
Why?
|
| Histoplasma | 1 | 2015 | 37 | 0.120 |
Why?
|
| Cushing Syndrome | 1 | 2015 | 22 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2015 | 13 | 0.120 |
Why?
|
| Protein-Losing Enteropathies | 1 | 2015 | 19 | 0.120 |
Why?
|
| Bronchiectasis | 1 | 2015 | 22 | 0.120 |
Why?
|
| Thyroid Nodule | 1 | 2015 | 22 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2018 | 1874 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2015 | 59 | 0.110 |
Why?
|
| Histoplasmosis | 1 | 2015 | 55 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 967 | 0.110 |
Why?
|
| Eosinophilia | 1 | 2016 | 105 | 0.110 |
Why?
|
| Severe Combined Immunodeficiency | 1 | 2015 | 104 | 0.110 |
Why?
|
| Stomach | 1 | 2017 | 267 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 5170 | 0.110 |
Why?
|
| Mutation | 2 | 2020 | 5944 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 167 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1105 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2016 | 348 | 0.110 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 431 | 0.110 |
Why?
|
| Pollen | 1 | 2014 | 49 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 542 | 0.100 |
Why?
|
| Fungi | 1 | 2014 | 72 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2018 | 1201 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2024 | 1350 | 0.100 |
Why?
|
| Anus Diseases | 1 | 2013 | 15 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 323 | 0.100 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2021 | 219 | 0.090 |
Why?
|
| Child, Preschool | 8 | 2020 | 14512 | 0.090 |
Why?
|
| Allergens | 1 | 2014 | 346 | 0.090 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 409 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 565 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2013 | 290 | 0.080 |
Why?
|
| Female | 14 | 2024 | 68816 | 0.080 |
Why?
|
| Infant | 6 | 2024 | 12842 | 0.080 |
Why?
|
| Thyroidectomy | 2 | 2021 | 101 | 0.080 |
Why?
|
| Young Adult | 6 | 2020 | 9704 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1759 | 0.070 |
Why?
|
| Liver | 1 | 2016 | 1765 | 0.070 |
Why?
|
| Biopsy | 3 | 2017 | 1239 | 0.070 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2007 | 36 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 1167 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2020 | 425 | 0.060 |
Why?
|
| Vimentin | 1 | 2007 | 63 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2020 | 12600 | 0.060 |
Why?
|
| Antigens, CD | 1 | 2007 | 415 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 4804 | 0.050 |
Why?
|
| R-SNARE Proteins | 1 | 2024 | 22 | 0.050 |
Why?
|
| Pneumonia | 2 | 2020 | 336 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2021 | 17111 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 1598 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 525 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2024 | 136 | 0.050 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2007 | 727 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2022 | 31 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 2852 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 32 | 0.040 |
Why?
|
| Phenotype | 2 | 2024 | 4308 | 0.040 |
Why?
|
| Adult | 4 | 2024 | 30628 | 0.040 |
Why?
|
| Vomiting | 1 | 2020 | 100 | 0.040 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 2020 | 59 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2024 | 652 | 0.040 |
Why?
|
| Drosophila | 1 | 2024 | 768 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2024 | 3273 | 0.040 |
Why?
|
| Alleles | 1 | 2024 | 1609 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2018 | 185 | 0.040 |
Why?
|
| Drosophila Proteins | 1 | 2024 | 757 | 0.030 |
Why?
|
| DiGeorge Syndrome | 1 | 2018 | 79 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 2017 | 13 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2021 | 554 | 0.030 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 46 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 1429 | 0.030 |
Why?
|
| Nitrosation | 1 | 2016 | 4 | 0.030 |
Why?
|
| Galectins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2021 | 778 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 66 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 689 | 0.030 |
Why?
|
| Sarcoma, Ewing | 1 | 2017 | 111 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 948 | 0.030 |
Why?
|
| Blood Proteins | 1 | 2016 | 131 | 0.030 |
Why?
|
| Chimerism | 1 | 2015 | 28 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8391 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 120 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2015 | 240 | 0.030 |
Why?
|
| Telomerase | 1 | 2015 | 153 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2017 | 300 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 1140 | 0.030 |
Why?
|
| beta Catenin | 1 | 2015 | 206 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2016 | 282 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2015 | 204 | 0.030 |
Why?
|
| Papilloma | 1 | 2013 | 22 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 637 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 786 | 0.030 |
Why?
|
| Proton Pump Inhibitors | 1 | 2016 | 274 | 0.020 |
Why?
|
| Infliximab | 1 | 2013 | 65 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2016 | 467 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2895 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 1231 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 377 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 2050 | 0.020 |
Why?
|
| Urban Population | 1 | 1994 | 276 | 0.020 |
Why?
|
| Proteomics | 1 | 2016 | 569 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1204 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 1657 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1994 | 395 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 875 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 900 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 2240 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2021 | 3080 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 2587 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2814 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1206 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2013 | 989 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3254 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1994 | 3938 | 0.010 |
Why?
|
| Animals | 1 | 2024 | 33175 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 10645 | 0.010 |
Why?
|
| Matched-Pair Analysis | 1 | 1994 | 28 | 0.010 |
Why?
|
| Peru | 1 | 1994 | 56 | 0.010 |
Why?
|
| Bias | 1 | 1994 | 137 | 0.010 |
Why?
|
| Dyspnea | 1 | 1994 | 156 | 0.010 |
Why?
|
| Fever | 1 | 1994 | 309 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1994 | 2082 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 1994 | 3336 | 0.000 |
Why?
|